Defilade Capital Management L.P. Purchases 273,677 Shares of Eledon Pharmaceuticals, Inc. $ELDN

Posted by Francis Steltz on Aug 3rd, 2026

Defilade Capital Management L.P. raised its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) by 8.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,564,127 shares of the company’s stock after buying an additional 273,677 shares during the period. Eledon Pharmaceuticals accounts for 1.5% of Defilade Capital Management L.P.’s investment portfolio, making the stock its 28th biggest holding. Defilade Capital Management L.P. owned 4.62% of Eledon Pharmaceuticals worth $10,978,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of Eledon Pharmaceuticals by 78.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 258,106 shares of the company’s stock worth $875,000 after buying an additional 113,261 shares during the last quarter. Jane Street Group LLC increased its position in shares of Eledon Pharmaceuticals by 83.7% during the first quarter. Jane Street Group LLC now owns 224,600 shares of the company’s stock valued at $761,000 after acquiring an additional 102,325 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Eledon Pharmaceuticals by 107.6% during the second quarter. Geode Capital Management LLC now owns 1,383,940 shares of the company’s stock worth $3,751,000 after acquiring an additional 717,223 shares during the period. JPMorgan Chase & Co. bought a new stake in Eledon Pharmaceuticals during the second quarter worth $75,000. Finally, American Century Companies Inc. purchased a new position in Eledon Pharmaceuticals in the second quarter worth $96,000. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Stock Performance

NASDAQ:ELDN opened at $3.38 on Monday. The stock has a market capitalization of $260.90 million, a PE ratio of -4.39 and a beta of 0.98. The firm’s 50 day moving average is $3.76 and its 200 day moving average is $3.19. Eledon Pharmaceuticals, Inc. has a 12 month low of $1.35 and a 12 month high of $4.60.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.11). Research analysts predict that Eledon Pharmaceuticals, Inc. will post -0.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ELDN. Rodman & Renshaw started coverage on Eledon Pharmaceuticals in a research note on Tuesday, July 21st. They issued a “buy” rating and a $12.00 price objective for the company. Wall Street Zen cut Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a report on Wednesday, June 24th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.67.

View Our Latest Stock Analysis on ELDN

Eledon Pharmaceuticals Profile

(Free Report)

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.